Industry
Hundreds of firms join global hunt for copycat biotech drugs
Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector.
Dollar surges anew, euro zone data eyed
The dollar rose to new multi-year highs against the yen, euro and a basket of currencies on Monday, a three-month-old rally showing no signs of dissipating before a week of important economic set pieces.
Six years after AIG bailout, trial asks: was it legal?
One of the more unusual trials to come out of the 2008 financial crisis is set to begin on Monday, when a federal judge will consider whether the U.S. government's rescue of American International Group Inc (AIG.N) was, in fact, legal.
Mercuria's third founder: China head eyes long game
The little known Asia head of Mercuria will be key in tying the Swiss commodity trader's $3.5 billion acquisition of JP Morgan Chase and Co's physical commodity desk into the company's China business.




